Abstract
T he dynamics of the erectile dysfunction (ED) market must be among the most difficult to predict. After all, few areas of medicine are as politically loaded and surrounded by so many unanswered questions. Nevertheless, analysts recently suggested that sales of existing therapies and the numerous new ED drugs in development could top $US4 billion within 3 years.
This is a preview of subscription content, log in via an institution to check access.
Rights and permissions
About this article
Cite this article
Greener, M. ED treatments. Pharmacoecon. Outcomes News 226, 3–4 (1999). https://doi.org/10.1007/BF03275043
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03275043